These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 37364785

  • 1. Exploring the influence of magnesium stearate content and mixing modality on the rheological properties and in vitro aerosolization of dry powder inhaler.
    Li J, Ma S, He X, Sun Y, Zhang X, Guan J, Mao S.
    Int J Pharm; 2023 Jul 25; 642():123179. PubMed ID: 37364785
    [Abstract] [Full Text] [Related]

  • 2. Synergistic effect of magnesium stearate and fine lactose in improving aerosolization performance of fluticasone propionate in dry powder formulation.
    He X, Li J, Wen X, Ma S, An Y, Zhang X, Guan J, Mao S.
    Int J Pharm; 2024 Oct 25; 664():124609. PubMed ID: 39163928
    [Abstract] [Full Text] [Related]

  • 3. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW, Schneider M, Morrical BD, Imanidis G.
    J Pharm Sci; 2018 Apr 25; 107(4):984-998. PubMed ID: 29247741
    [Abstract] [Full Text] [Related]

  • 4. Role of dispersion enhancer selection in the development of novel tratinterol hydrochloride dry powder inhalation formulations.
    Liu T, Tong S, Liao Q, Pan L, Cheng M, Rantanen J, Cun D, Yang M.
    Int J Pharm; 2023 Mar 25; 635():122702. PubMed ID: 36773729
    [Abstract] [Full Text] [Related]

  • 5. Predicting in vitro lung deposition behavior of combined dry powder inhaler via rheological properties.
    Li J, Ma S, Sun Y, Song R, Cai B, Li H, Chen Y, Zhang X, Guan J, Mao S.
    Eur J Pharm Biopharm; 2022 Dec 25; 181():195-206. PubMed ID: 36400254
    [Abstract] [Full Text] [Related]

  • 6. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS, Kim JH, Jin SG, Kim DW, Kim JO, Yong CS, Youn YS, Oh KT, Woo JS, Choi HG.
    Pharm Dev Technol; 2018 Feb 25; 23(2):158-166. PubMed ID: 28612675
    [Abstract] [Full Text] [Related]

  • 7. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ, Jain RR, Soni PS, Abdul S, Darshana H, Gaikwad RV, Menon MD.
    J Aerosol Med Pulm Drug Deliv; 2015 Aug 25; 28(4):254-67. PubMed ID: 25517187
    [Abstract] [Full Text] [Related]

  • 8. Exploring the potential influence of drug charge on downstream deposition behaviour of DPI powders.
    Sun Y, Cui Z, Sun Y, Qin L, Zhang X, Liu Q, Shen X, Yu D, Mao S.
    Int J Pharm; 2020 Oct 15; 588():119798. PubMed ID: 32828976
    [Abstract] [Full Text] [Related]

  • 9. Elucidation of lactose fine size and drug shape on rheological properties and aerodynamic behavior of dry powders for inhalation.
    Sun Y, Yu D, Li J, Zhao J, Feng Y, Zhang X, Mao S.
    Eur J Pharm Biopharm; 2022 Oct 15; 179():47-57. PubMed ID: 36029939
    [Abstract] [Full Text] [Related]

  • 10. Effect of magnesium stearate surface coating method on the aerosol performance and permeability of micronized fluticasone propionate.
    Kumar V, Sethi B, Yanez E, Leung DH, Ghanwatkar YY, Cheong J, Tso J, Narang AS, Nagapudi K, Mahato RI.
    Int J Pharm; 2022 Mar 05; 615():121470. PubMed ID: 35041913
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN, Robins E, Flament MP.
    Eur J Pharm Biopharm; 2012 Apr 05; 80(3):596-603. PubMed ID: 22198291
    [Abstract] [Full Text] [Related]

  • 13. Stability test of novel combined formulated dry powder inhalation system containing antibiotic: physical characterization and in vitro-in silico lung deposition results.
    Benke E, Farkas Á, Balásházy I, Szabó-Révész P, Ambrus R.
    Drug Dev Ind Pharm; 2019 Aug 05; 45(8):1369-1378. PubMed ID: 31096805
    [Abstract] [Full Text] [Related]

  • 14. The Relationship Between the Permeability and the Performance of Carrier-Based Dry Powder Inhalation Mixtures: New Insights and Practical Guidance.
    Shalash AO, Khalafallah NM, Molokhia AM, Elsayed MMA.
    AAPS PharmSciTech; 2018 Feb 05; 19(2):912-922. PubMed ID: 29063377
    [Abstract] [Full Text] [Related]

  • 15. Exploring the influence of drug content on DPI powder properties and potential prediction of pulmonary drug deposition.
    Sun Y, Qin L, Liu C, Su J, Zhang X, Yu D, Guo C, Lu H, Li L, Xiong W, Mao S.
    Int J Pharm; 2020 Feb 15; 575():119000. PubMed ID: 31893544
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Correlations between surface composition and aerosolization of jet-milled dry powder inhaler formulations with pharmaceutical lubricants.
    Mangal S, Park H, Nour R, Shetty N, Cavallaro A, Zemlyanov D, Thalberg K, Puri V, Nicholas M, Narang AS, Zhou QT.
    Int J Pharm; 2019 Sep 10; 568():118504. PubMed ID: 31299339
    [Abstract] [Full Text] [Related]

  • 20. An investigation into the effect of fine lactose particles on the fluidization behaviour and aerosolization performance of carrier-based dry powder inhaler formulations.
    Kinnunen H, Hebbink G, Peters H, Shur J, Price R.
    AAPS PharmSciTech; 2014 Aug 10; 15(4):898-909. PubMed ID: 24756910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.